Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-224 in Essential Hypertension
NCT06291207Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AD-224C in essential hypertension, sponsored by Addpharma, Inc.. Started Apr 2024; status: completed.
02
Drugs
AD-224C
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06291207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291207.